Regenxbio scores $180M vector deal; Bristol-Myers expands agreement to test Opdivo with Infinity's IPI-549
→ Abeona Therapeutics $ABEO has licensed Regenxbio’s $RGNX NAV AAV9 vector for four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
